Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the japan dialysis outcomes and practice patterns study

Nephron - Clinical Practice

Volumn 122, Issue 1-2, 2013, Pages 24-32

  Fujikawa, Tetsuya ^a,b,h   Ikeda, Yumiko ^b   Fukuhara, Shunichi ^c   Akiba, Takashi ^d   Akizawa, Tadao ^e   Kurokawa, Kiyoshi ^f   Saito, Akira ^g  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Yokohama Minami Kyosai Hospital   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

^g TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NONE   (Japan)

Author keywords

Anemia; Erythropoiesis stimulating agent resistance index; Hemodialysis; Mortality; Variability of erythropoiesis stimulating agent resistance index

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; C REACTIVE PROTEIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; COMORBIDITY; CONTROLLED STUDY; DOPPS III; DRUG EFFICACY; ESA RESISTANCE INDEX; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DRUG RESISTANCE; FEMALE; HEMATINICS; HUMANS; JAPAN; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS;

EID: 84874794262     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000346740     Document Type: Article

References (25)

1. Collins AJ, Foley RN, Herzog C, Chavers BM, et al: Excerpts from the US Renal Data System Annual Data Report. Am J Kidney Dis 2010; 55:S1-S420, A6-7.
2. Nakai S, Suzuki K, Masakane I, et al: Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 2010; 14: 505-540.
3. Ansell D, Roderick P, Steenkamp R, et al: UK Renal Registry 12th Annual Report (December 2009): chapter 7: survival and causes of death of UK adult patients on renal replacement therapy in 2008: national and centrespecific analyses. Nephron Clin Pract 2010; 115:c117-c144.
4. Port FK, Wolfe RA, Hulbert-Shearon TE, et al: High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis 2004; 43: 1014-1023.
5. Young EW, Albert JM, Satayathum S, et al: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
6. Pifer TB, McCullough KP, Port FK, et al: Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-2245.
7. Locatelli F, Pisoni RL, Combe C, et al: Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132.
8. Dhingra RK, Young EW, Hulbert-Shearon TE, et al: Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443-1451.
9. Pisoni RL, Young EW, Combe C, et al: Higher catheter use within facilities is associated with increased mortality and hospitalization: results from the DOPPS. J Am Soc Nephrol 2001; 12: 299A.
10. Johnson JG, Gore SM, Firth J: The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature. Nephrol Dial Transplant 1999; 14: 2156-2164.
11. Zhang Y, Thamer M, Stefanik K, et al: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876.
12. Lopez-Gomez JM, Portoles JM, Aljama P: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int 2008; 74:S75-S81.
13. Panichi V, Rosati A, Bigazzi R, et al: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648.
14. Pisoni RL, Gillespie BW, Dickinson DM, et al: The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004; 44:S7-S15.
15. Young EW, Goodkin DA, Mapes DL, et al: The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int 2000; 57:S74-S81.
16. Macdougall IC, Gray SJ, Elston O, et al: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395.
17. Locatelli F, Olivares J, Walker R, et al: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747.
18. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 1205-1210.
19. SAS Institute. SAS/STAT User's Guide, Version 8, Vol. 2. Cary, SAS Institute, 2000.
20. Whitehead TP, Robinson D, Hale AC, et al: Clinical Chemistry and Haematology: Adults Reference Values. London, BUPA Medical Research,1994, pp 48-49.
21. Morceau F, Dicato M, Diederich M: Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators Inflamm 2009; 2009: 405016.
22. Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M: Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood Purif 2012; 33: 238-244.
23. Guerrero-Riscos MA, Montes-Delgado R, Seda-Guzman M, Praena-Fernandez JM: Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease. Nefrologia 2012; 32: 343-352.
24. Pereira BJ: Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis. Nephrol Dial Transplant 1995; 10: 27-32.
25. Krantz SB: Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994; 307: 353-359.